Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides
Phosphodiesterase-5 (PDE5) inhibitors and other agents that modulate intracellular cGMP are now emerging as promising, safe, and easy to administer therapies for pulmonary hypertension, with relatively few side effects. Recent studies have shown that PDE5 inhibitors are potent acute pulmonary vasodi...
Gespeichert in:
| Veröffentlicht in: | Current opinion in pharmacology 2005-06, Vol.5 (3), p.245-250 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 250 |
|---|---|
| container_issue | 3 |
| container_start_page | 245 |
| container_title | Current opinion in pharmacology |
| container_volume | 5 |
| creator | Steiner, M Kathryn Preston, Ioana R Klinger, James R Hill, Nicholas S |
| description | Phosphodiesterase-5 (PDE5) inhibitors and other agents that modulate intracellular cGMP are now emerging as promising, safe, and easy to administer therapies for pulmonary hypertension, with relatively few side effects. Recent studies have shown that PDE5 inhibitors are potent acute pulmonary vasodilators in experimental models that partially reverse established pulmonary arterial hypertension and blunt chronic pulmonary hypertension. In addition, studies on animals reveal that PDE5 inhibitors work in concert with nitric oxide and/or natriuretic peptide levels by enhancing intracellular cGMP and cGMP-mediated vasodilator effects. Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP also yields additive beneficial effects on pulmonary hemodynamics in patients with pulmonary arterial hypertension. |
| doi_str_mv | 10.1016/j.coph.2004.12.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67857240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1471489205000457</els_id><sourcerecordid>67857240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-cd4d6cf013620929c4b961f6f934bb74a613afc7226ee1e3a3f0791ff483f9e53</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7rr6BzxIT55szVfbjXiRxS9YUEHPIU0nbJZuWpNW3H9vyq548zQD88zLzIPQOcEZwaS4Xme67VYZxZhnhGYYzw_QlPCSpFyU7PC3nws6QSchrDEmOWPlMZqQXOBSEDxFb69Ds2md8ttkte3A9-CCbd1NYt1KNVAnzvbe6qT9tjVcJcE2NThlbJMoF4cqDgcPfSQ66PrIhFN0ZFQT4GxfZ-jj4f598ZQuXx6fF3fLVLOc96mueV1ogwkrKBZUaF6JgpjCCMarquSqIEwZXVJaABBgipnxZGP4nBkBOZuhy11u59vPAUIvNzZoaBrloB2CLMp5XlKOI0h3oPZtCB6M7LzdxI8lwXIUKddyFClHkZJQGUXGpYt9-lBtoP5b2ZuLwO0OgPjjlwUvg7bgNNTWg-5l3dr_8n8AVRSFeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67857240</pqid></control><display><type>article</type><title>Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Steiner, M Kathryn ; Preston, Ioana R ; Klinger, James R ; Hill, Nicholas S</creator><creatorcontrib>Steiner, M Kathryn ; Preston, Ioana R ; Klinger, James R ; Hill, Nicholas S</creatorcontrib><description>Phosphodiesterase-5 (PDE5) inhibitors and other agents that modulate intracellular cGMP are now emerging as promising, safe, and easy to administer therapies for pulmonary hypertension, with relatively few side effects. Recent studies have shown that PDE5 inhibitors are potent acute pulmonary vasodilators in experimental models that partially reverse established pulmonary arterial hypertension and blunt chronic pulmonary hypertension. In addition, studies on animals reveal that PDE5 inhibitors work in concert with nitric oxide and/or natriuretic peptide levels by enhancing intracellular cGMP and cGMP-mediated vasodilator effects. Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP also yields additive beneficial effects on pulmonary hemodynamics in patients with pulmonary arterial hypertension.</description><identifier>ISSN: 1471-4892</identifier><identifier>EISSN: 1471-4973</identifier><identifier>DOI: 10.1016/j.coph.2004.12.008</identifier><identifier>PMID: 15907910</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>3',5'-Cyclic-GMP Phosphodiesterases ; Administration, Inhalation ; Adult ; Animals ; Bronchodilator Agents - administration & dosage ; Bronchodilator Agents - therapeutic use ; Clinical Trials as Topic ; Cyclic GMP - physiology ; Cyclic Nucleotide Phosphodiesterases, Type 5 ; Humans ; Hypertension, Pulmonary - drug therapy ; Nitric Oxide - administration & dosage ; Nitric Oxide - therapeutic use ; Phosphodiesterase Inhibitors - therapeutic use ; Phosphoric Diester Hydrolases - adverse effects ; Piperazines - therapeutic use ; Purines ; Sildenafil Citrate ; Sulfones</subject><ispartof>Current opinion in pharmacology, 2005-06, Vol.5 (3), p.245-250</ispartof><rights>2004 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-cd4d6cf013620929c4b961f6f934bb74a613afc7226ee1e3a3f0791ff483f9e53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.coph.2004.12.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15907910$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Steiner, M Kathryn</creatorcontrib><creatorcontrib>Preston, Ioana R</creatorcontrib><creatorcontrib>Klinger, James R</creatorcontrib><creatorcontrib>Hill, Nicholas S</creatorcontrib><title>Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides</title><title>Current opinion in pharmacology</title><addtitle>Curr Opin Pharmacol</addtitle><description>Phosphodiesterase-5 (PDE5) inhibitors and other agents that modulate intracellular cGMP are now emerging as promising, safe, and easy to administer therapies for pulmonary hypertension, with relatively few side effects. Recent studies have shown that PDE5 inhibitors are potent acute pulmonary vasodilators in experimental models that partially reverse established pulmonary arterial hypertension and blunt chronic pulmonary hypertension. In addition, studies on animals reveal that PDE5 inhibitors work in concert with nitric oxide and/or natriuretic peptide levels by enhancing intracellular cGMP and cGMP-mediated vasodilator effects. Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP also yields additive beneficial effects on pulmonary hemodynamics in patients with pulmonary arterial hypertension.</description><subject>3',5'-Cyclic-GMP Phosphodiesterases</subject><subject>Administration, Inhalation</subject><subject>Adult</subject><subject>Animals</subject><subject>Bronchodilator Agents - administration & dosage</subject><subject>Bronchodilator Agents - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Cyclic GMP - physiology</subject><subject>Cyclic Nucleotide Phosphodiesterases, Type 5</subject><subject>Humans</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Nitric Oxide - administration & dosage</subject><subject>Nitric Oxide - therapeutic use</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Phosphoric Diester Hydrolases - adverse effects</subject><subject>Piperazines - therapeutic use</subject><subject>Purines</subject><subject>Sildenafil Citrate</subject><subject>Sulfones</subject><issn>1471-4892</issn><issn>1471-4973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMo7rr6BzxIT55szVfbjXiRxS9YUEHPIU0nbJZuWpNW3H9vyq548zQD88zLzIPQOcEZwaS4Xme67VYZxZhnhGYYzw_QlPCSpFyU7PC3nws6QSchrDEmOWPlMZqQXOBSEDxFb69Ds2md8ttkte3A9-CCbd1NYt1KNVAnzvbe6qT9tjVcJcE2NThlbJMoF4cqDgcPfSQ66PrIhFN0ZFQT4GxfZ-jj4f598ZQuXx6fF3fLVLOc96mueV1ogwkrKBZUaF6JgpjCCMarquSqIEwZXVJaABBgipnxZGP4nBkBOZuhy11u59vPAUIvNzZoaBrloB2CLMp5XlKOI0h3oPZtCB6M7LzdxI8lwXIUKddyFClHkZJQGUXGpYt9-lBtoP5b2ZuLwO0OgPjjlwUvg7bgNNTWg-5l3dr_8n8AVRSFeg</recordid><startdate>20050601</startdate><enddate>20050601</enddate><creator>Steiner, M Kathryn</creator><creator>Preston, Ioana R</creator><creator>Klinger, James R</creator><creator>Hill, Nicholas S</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050601</creationdate><title>Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides</title><author>Steiner, M Kathryn ; Preston, Ioana R ; Klinger, James R ; Hill, Nicholas S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-cd4d6cf013620929c4b961f6f934bb74a613afc7226ee1e3a3f0791ff483f9e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>3',5'-Cyclic-GMP Phosphodiesterases</topic><topic>Administration, Inhalation</topic><topic>Adult</topic><topic>Animals</topic><topic>Bronchodilator Agents - administration & dosage</topic><topic>Bronchodilator Agents - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Cyclic GMP - physiology</topic><topic>Cyclic Nucleotide Phosphodiesterases, Type 5</topic><topic>Humans</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Nitric Oxide - administration & dosage</topic><topic>Nitric Oxide - therapeutic use</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Phosphoric Diester Hydrolases - adverse effects</topic><topic>Piperazines - therapeutic use</topic><topic>Purines</topic><topic>Sildenafil Citrate</topic><topic>Sulfones</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Steiner, M Kathryn</creatorcontrib><creatorcontrib>Preston, Ioana R</creatorcontrib><creatorcontrib>Klinger, James R</creatorcontrib><creatorcontrib>Hill, Nicholas S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Steiner, M Kathryn</au><au>Preston, Ioana R</au><au>Klinger, James R</au><au>Hill, Nicholas S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides</atitle><jtitle>Current opinion in pharmacology</jtitle><addtitle>Curr Opin Pharmacol</addtitle><date>2005-06-01</date><risdate>2005</risdate><volume>5</volume><issue>3</issue><spage>245</spage><epage>250</epage><pages>245-250</pages><issn>1471-4892</issn><eissn>1471-4973</eissn><abstract>Phosphodiesterase-5 (PDE5) inhibitors and other agents that modulate intracellular cGMP are now emerging as promising, safe, and easy to administer therapies for pulmonary hypertension, with relatively few side effects. Recent studies have shown that PDE5 inhibitors are potent acute pulmonary vasodilators in experimental models that partially reverse established pulmonary arterial hypertension and blunt chronic pulmonary hypertension. In addition, studies on animals reveal that PDE5 inhibitors work in concert with nitric oxide and/or natriuretic peptide levels by enhancing intracellular cGMP and cGMP-mediated vasodilator effects. Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP also yields additive beneficial effects on pulmonary hemodynamics in patients with pulmonary arterial hypertension.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15907910</pmid><doi>10.1016/j.coph.2004.12.008</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-4892 |
| ispartof | Current opinion in pharmacology, 2005-06, Vol.5 (3), p.245-250 |
| issn | 1471-4892 1471-4973 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67857240 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | 3',5'-Cyclic-GMP Phosphodiesterases Administration, Inhalation Adult Animals Bronchodilator Agents - administration & dosage Bronchodilator Agents - therapeutic use Clinical Trials as Topic Cyclic GMP - physiology Cyclic Nucleotide Phosphodiesterases, Type 5 Humans Hypertension, Pulmonary - drug therapy Nitric Oxide - administration & dosage Nitric Oxide - therapeutic use Phosphodiesterase Inhibitors - therapeutic use Phosphoric Diester Hydrolases - adverse effects Piperazines - therapeutic use Purines Sildenafil Citrate Sulfones |
| title | Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T01%3A21%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pulmonary%20hypertension:%20inhaled%20nitric%20oxide,%20sildenafil%20and%20natriuretic%20peptides&rft.jtitle=Current%20opinion%20in%20pharmacology&rft.au=Steiner,%20M%20Kathryn&rft.date=2005-06-01&rft.volume=5&rft.issue=3&rft.spage=245&rft.epage=250&rft.pages=245-250&rft.issn=1471-4892&rft.eissn=1471-4973&rft_id=info:doi/10.1016/j.coph.2004.12.008&rft_dat=%3Cproquest_cross%3E67857240%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67857240&rft_id=info:pmid/15907910&rft_els_id=S1471489205000457&rfr_iscdi=true |